Pharminent · Daily Brief
October 16, 2026
Regulatory & Approvals
CHMP recommends Revolution Medicines’ Rasonque for metastatic pancreatic cancer
EMA’s human medicines committee recommended granting a marketing authorization in the European Union for Rasonque (daraxonrasib), an oral treatment for adults with metastatic pancreatic cancer, from Revolution Medicines Netherlands B.V.
EMA →
CHMP recommends six new medicines at October 2026 meeting
At its October 12-15, 2026 meeting, EMA’s CHMP recommended six medicines for approval, including Foundayo (orforglipron) from Eli Lilly Nederland B.V., Rasonque (daraxonrasib) from Revolution Medicines Netherlands B.V., and Yuviwel.
EMA →$LLY
FDA approves Roche’s Enspryng for thyroid eye disease
Roche has won US approval for Enspryng in a second indication, thyroid eye disease.
Pharmaphorum →$RHHBY
Clinical Data
Verastem reports early data for KRAS G12D inhibitor in pancreatic cancer
Verastem Oncology reported encouraging early results for its KRAS G12D inhibitor, which is being studied in more than 200 patients with advanced solid tumors including metastatic pancreatic ductal adenocarcinoma.
STAT →
Deals & Partnerships
AstraZeneca and insitro sign cardiometabolic AI deal worth up to $1.5B
AstraZeneca and insitro have formed an AI-powered drug discovery partnership in cardiometabolic disease worth up to $1.5 billion, with a focus that includes MASH.
Pharmaceutical Technology →$AZN
Armed Cell Therapeutics takes over Lakefront’s divested cell therapies
Armed Cell Therapeutics, a Belgian startup chaired by former Galapagos CEO Paul Stoffels, has assumed control of the cell therapy programs divested by the company now known as Lakefront Biotherapeutics in a strategic overhaul.
BioPharma Dive →
Business & Finance
City Therapeutics prices $200M IPO for RNAi pipeline
RNAi drugmaker City Therapeutics priced a $200 million IPO, with proceeds supporting three medicines in or nearing clinical testing and earlier research into RNAi treatments that reach tissues outside the liver.
BioPharma Dive →
Iambic Therapeutics raises $150M in IPO for AI-driven cancer pipeline
AI-enabled biotech Iambic Therapeutics raised $150 million in its IPO and will apply the proceeds toward clinical development of its internally discovered, wholly owned cancer drugs. The company also has R&D alliances with companies including Bayer and AbbVie.
MedCity News →$ABBV$BAYRY
Estuary launches with $93M Series A for ADPKD genetic medicines
Biogen-backed Estuary raised a $93 million Series A led by RA Capital to fund development of two genetic medicines for the inherited kidney disorder ADPKD.
BioPharma Dive →$BIIB
Acta Pharmaceuticals raises $24M seed for Alzheimer’s pipeline
Acta Pharmaceuticals secured $24 million in seed funding to advance a pipeline focused on early intervention and prevention of Alzheimer’s disease, including clinical progression of lead candidate GSM-779690T.
Pharmaceutical Technology →
Sterling doubles ADC manufacturing capacity at Deeside, Wales site
Sterling Pharma Solutions completed a multi-million-pound expansion of its bioconjugation facility in Deeside, Wales, doubling manufacturing capacity and increasing batch scale to 500 liters. The expansion adds a GMP manufacturing suite with a 500-liter reactor and a 1,400-square-foot Grade C cleanroom.
PharmaFile →
Forwarded this? Get your copy free
Sign up free →
Pharminent — Competitive Intelligence Suite · Tickers link to Yahoo Finance for reference only. Editorial framings are analysis, not investment advice. © 2026.